The CDSCO's approval of Boehringer Ingelheim's Jardiance (empagliflozin) 10mg tablets for treating chronic kidney disease (CKD) in India marks a significant advancement in addressing the rising health concern.

According to the company's statement, Jardiance is specifically approved to reduce the risk of sustained decline in eGFR for adults with CKD at risk of progression, encompassing a crucial segment of over 33 million adults in India facing CKD challenges.

Gagandeep Singh Bedi, Managing Director of Boehringer Ingelheim India, emphasized the potential of Jardiance in playing an essential role in improving outcomes for people with kidney disease.

Chronic kidney disease has become a major health issue in India, ranking among the top 10 causes of death. The approval not only provides an innovative treatment option but also aligns with the commitment to address unmet medical needs in the country.

Dr. Shraddha Bhure, Medical Director at Boehringer Ingelheim India, highlighted the impact of CKD on patients, including increased risks of hospital admissions, cardiac events, kidney failure, and death.

The approval of empagliflozin, backed by scientific evidence, offers a promising solution to enhance the current CKD treatment landscape. Optimal management of CKD is expected to yield significant improvements in health and economic outcomes for patients, families, and the broader healthcare system.

The EMPA-KIDNEY phase III trial established Jardiance's efficacy in significantly reducing the risk of kidney disease progression and cardiovascular death in eligible CKD patients.

The approval sets the stage for transforming CKD care in India, addressing both the clinical and economic challenges associated with the disease. Boehringer Ingelheim's commitment to providing innovative solutions aligns with the evolving healthcare needs, offering hope for improved outcomes and quality of life for individuals grappling with chronic kidney disease.